Kronos Bio Inc (OQ:KRON)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1300 S. El Camino Real, Suite 300
SAN MATEO CA 94402
Tel: N/A
Website: https://kronosbio.com
IR: See website
<
Key People
Arie S. Belldegrun
Chairman of the Board
Norbert W. Bischofberger
President, Chief Executive Officer, Director
Barbara A. Kosacz
Chief Operating Officer, General Counsel
Jorge DiMartino
Executive Vice President - Clinical Development, Chief Medical Officer
Christopher Dinsmore
Chief Scientific Officer
 
Business Overview
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine's small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. It is initial development focus for KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).
Financial Overview
For the six months ended 30 June 2020, Kronos BioInc revenues was not reported. Net loss increased from$6.6M to $15.6M. Higher net loss reflects Research anddevelopment - Balancing val increase from $5.2M to $13.1M(expense), General and administrative - Balancing vincrease of 80% to $2.6M (expense), Stock-basedCompensation in R&D increase from $11K to $295K (expense).
Employees: 45 as of Jul 15, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $1,699M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$25.75M as of Jun 30, 2020
Net annual income (TTM): -$25.05M as of Jun 30, 2020
Free cash flow (TTM): -$24.24M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 13,157,895 as of Sep 18, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.